Comorbid Hypertension in Cancer Patients Undergoing Treatment: A Perspective

Abstract Hypertension (HTN) is the most common comorbidity among cancer patients and it can also be a consequence of cancer therapy. The appropriate management of HTN results in avoiding the adverse cardiovascular events such as coronary heart disease, heart failure, stroke, end-stage renal failure, and overall mortality. A hospital-based cross-sectional study was conducted on 50 cancer patients undergoing treatment at Healthcare Global hospital during the period November 2024 to January 2025. Out of this initial cohort of 50 patients, a series of 10 cases with large variation in levels of blood pressure (BP) were recorded across six timeframes of treatment. This case series of 10 patients includes both new onset and old cases of HTN. For the initial cohort of 50 cancer patients, the mean or median measure of HTN is not an ideal statistic as they currently appear less extreme than when the abnormal values were not regressed. Among the 10 patients chosen from the initial 50, 3 patients had prior history of HTN and 4 patients were incident cases of HTN. Also, the anti-HTN treatment was revised or newly initiated for a total of 4 cancer patients. It is essential to assess BP at baseline (initiation of chemotherapy) and during subsequent visits to the clinic. The choice of anti-HTN drug depends on the pathophysiology, which in turn mandates the coalition between oncologists and cardiologists in achieving an adequate control of BP.

Authors

Institutions

Publication Details

Journal
Indian Journal of Medical and Paediatric Oncology
Published
2026-11-12
DOI
https://doi.org/10.1055/s-0046-1830007
Primary Topic
Chemotherapy-induced cardiotoxicity and mitigation
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Comorbid Hypertension in Cancer Patients Undergoing Treatment: A Perspective

Vinod K. Ramani, Radheshyam Naik, Ajaikumar Basavalinga Sadashivaiah, Aisiri HUV et al.
Indian Journal of Medical and Paediatric Oncology
Chemotherapy-induced cardiotoxicity and mitigation
article

Comorbid Hypertension in Cancer Patients Undergoing Treatment: A Perspective

Vinod K. Ramani, Radheshyam Naik, Ajaikumar Basavalinga Sadashivaiah, Aisiri HUV, Maanas R. Rao
article en

Abstract

Abstract Hypertension (HTN) is the most common comorbidity among cancer patients and it can also be a consequence of cancer therapy. The appropriate management of HTN results in avoiding the adverse cardiovascular events such as coronary heart disease, heart failure, stroke, end-stage renal failure, and overall mortality. A hospital-based cross-sectional study was conducted on 50 cancer patients undergoing treatment at Healthcare Global hospital during the period November 2024 to January 2025. Out of this initial cohort of 50 patients, a series of 10 cases with large variation in levels of blood pressure (BP) were recorded across six timeframes of treatment. This case series of 10 patients includes both new onset and old cases of HTN. For the initial cohort of 50 cancer patients, the mean or median measure of HTN is not an ideal statistic as they currently appear less extreme than when the abnormal values were not regressed. Among the 10 patients chosen from the initial 50, 3 patients had prior history of HTN and 4 patients were incident cases of HTN. Also, the anti-HTN treatment was revised or newly initiated for a total of 4 cancer patients. It is essential to assess BP at baseline (initiation of chemotherapy) and during subsequent visits to the clinic. The choice of anti-HTN drug depends on the pathophysiology, which in turn mandates the coalition between oncologists and cardiologists in achieving an adequate control of BP.

Indian Journal of Medical and Paediatric Oncology
Healthcare Global Enterprises (IN), R.V. College of Engineering (IN)
Good health and well-being
Chemotherapy-induced cardiotoxicity and mitigation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon